Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4410331 | 0.89 | SCARB1 (0.68) | SCARB1MAPK14 | |
| SCHEMBL4410336 | 0.89 | SCARB1 (0.68) | SCARB1MAPK14 | |
| SCHEMBL4949172 | 0.88 | SCARB1 (0.72) | SCARB1MAPK14 | |
| SCHEMBL1600035 | 0.88 | SCARB1 (0.74) | SCARB1MAPK14 | |
| SCHEMBL12669830 | 0.88 | SCARB1 (0.67) | SCARB1MAPK14 | |
| SCHEMBL1600149 | 0.85 | SCARB1 (1.00) | SCARB1MAPK14 | |
| SCHEMBL5820136 | 0.84 | SCARB1 (0.77) | SCARB1MAPK14 | |
| SCHEMBL4565126 | 0.81 | MAPK14 (0.65) | SCARB1MAPK14 | |
| SCHEMBL1602728 | 0.81 | MAPK14 (0.67) | SCARB1MAPK14 | |
| SCHEMBL1600228 | 0.81 | MAPK14 (0.57) | SCARB1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7749999-B2 | Alpha-ketoamides and derivatives thereof | ITHERX PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | claimed |
| US-20050107399-A1 | Cytokine inhibitors | KEMIA, INC. | 2005-05-19 | — | — | US | claimed |
| WO-2011063076-A1 | METHODS OF TREATING HEPATITIS C VIRUS WITH OXOACETAMIDE COMPOUNDS | ITHERX PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| US-20110117055-A1 | Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds | BRS - TUSTIN SAFEGUARD ASSOCIATES II, LLC | 2011-05-19 | — | — | US | disclosed |
| US-20110117055-A1 | Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds | BRS - TUSTIN SAFEGUARD ASSOCIATES II, LLC | 2011-05-19 | — | — | US | disclosed |
| US-7919617-B2 | Cytokine inhibitors | iTherX Pharmaceuticals Inc. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7897599-B2 | Cytokine inhibitors | iTherX Pharmaceuticals Inc. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20100273797-A1 | ALPHA-KETOAMIDES AND DERIVATIVES THEREOF | ITHERX PHARMACEUTICALS, INC. | 2010-10-28 | — | — | US | disclosed |
| US-7749999-B2 | Alpha-ketoamides and derivatives thereof | ITHERX PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20100093734-A1 | CYTOKINE INHIBITORS | ITHERX PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093735-A1 | CYTOKINE INHIBITORS | ITHERX PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20050107399-A1 | Cytokine inhibitors | KEMIA, INC. | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107399-A1 | Cytokine inhibitors | TNF, IL1RN, IL1A | SCARB1 425/4885MAPK14 371/4885 |
| US-20100093734-A1 | CYTOKINE INHIBITORS | TNF, IL1RN, IL1A | SCARB1 425/4885MAPK14 371/4885 |
| US-20100273797-A1 | ALPHA-KETOAMIDES AND DERIVATIVES THEREOF | TNF, IL1A, IL1B | SCARB1 2585/4885MAPK14 696/4885 |
| US-20110117055-A1 | Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds | OAT, HAVCR2, OTC | SCARB1 922/4885MAPK14 3352/4885 |
| US-20100093735-A1 | CYTOKINE INHIBITORS | TNF, IL1RN, IL1A | SCARB1 425/4885MAPK14 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.